


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 700603.7/1
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/508808
INTERNATIONAL APPLICATION NO. PCT/US03/09288	INTERNATIONAL FILING DATE 24 March 2003	PRIORITY DATE CLAIMED 22 March 2002
TITLE OF INVENTION TRANSGENIC AVES PRODUCING HUMAN POLYCLONAL ANTIBODIES		
APPLICANT(S) FOR DO/EO/US Robert J. ETCHES, Robert M. KAY, Philip LEIGHTON and Lei ZHU		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 37 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 to 20 below concern document(s) or information included: <ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31. An assignment of the invention to: <u>Origen Therapeutics</u> 13. <input type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items of information: 19 cited references 		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. 107508808		INTERNATIONAL APPLICATION NO. PCT/US03/09288	
		ATTORNEY'S DOCKET NUMBER 700603.7/1	
21. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):			
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1080.00			
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$920.00			
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$770.00			
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$730.00			
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provision of PCT Article 33(2)-(4).....\$100.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =		100.00	
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	20 - 20 =	0	x \$18.00
Independent claims	3 - 3 =	0	x \$86.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+\$290.00
TOTAL OF ABOVE CALCULATIONS =		100.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		50.00	
SUBTOTAL =		50.00	
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+	
TOTAL NATIONAL FEE =			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property		40.00	
TOTAL FEES ENCLOSED =		90.00	
		Amount to be Refunded:	\$
		Charged:	\$
<p>a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>15-0665</u> in the amount of \$ <u>\$90.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayments to Deposit Account No. <u>15-0665</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charges to a credit card. WARNING: Information on this form may be come public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>			
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO: Customer Number. <u>34313</u></p>			
<p>Orrick Herrington & Sutcliffe, LLP 4 Park Plaza, Suite 1600 Irvine, CA 92614 Tel: 949-567-6700 Fax: 949-567-6710</p>		<p> SIGNATURE: _____ NAME Kurt T. Mulville REGISTRATION NUMBER <u>37194</u></p>	

**THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

CERTIFICATE OF MAILING		To:	
		Assistant Commissioner for Patents Box DO/EO/US Washington, DC 20231 Facsimile (703) 305-3230	
Applicant's or agent's file reference: 700603.7/1			
International application No. (if known) PCT/US03/09288	International Filing date (day/month/year) (if known) 24 March 2003	(Earliest) Priority date (day/month/year) 22 March 2002	
U.S. Application No (if known)	U.S. Filing date (day/month/year)(if known) 22 September 2004		
Applicant Etches et al.			
Title of invention TRANSGENIC AVES PRODUCING HUMAN POLYCLONAL ANTIBODIES			

Sir:

Date of Deposit: 22 September 2004

Express Mail Label No. EV314509349US

I hereby certify that these papers and fee(s) are being deposited with the United States Postal Service on the date indicated above, as Express Mail, in an envelope addressed to Box PCT, Assistant Commissioner of Patents, Washington, DC 20231.

1. Transmittal Letter to the US Designated/Elected Office Concerning a filing under 37 USC 371 (2 pages)
2. Declaration
3. Information Disclosure Statement
4. Form 1449 (+19 cites)
5. Assignment Coversheet
6. Assignment document (6 pages)



Angela Wendel
 ORRICK, HERRINGTON & SUTCLIFFE LLP
 4 Park Plaza, Suite 1600
 Irvine, CA 92614-2558
 Telephone: (949) 567-6700
 Facsimile: (949) 567-6710